INS and obesity due to melanocortin 4 receptor deficiency: According to Pandeya and co-authors [189], RJ may be a potential drug in the treatment of obesity, given that the anti-adipogenic effect of 10-HDA on 3 T3-L1 adipocytes occurs via two mechanisms: the inhibition of the cAMP/PKA pathway and the inhibition of p-Akt- and MAPK-dependent insulin signaling pathways.